- Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry.
- Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug Product, while Waterstone will supply Linker-payload.
, /PRNewswire/ — Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, and Waterstone, a reliable partner for its worldwide customers through continuous improvement and innovation to ensure high quality and sustainable service, today announced a strategic partnership aimed at providing integrated services for Antibody-Drug Conjugate (ADC) industry worldwide.
Through this collaboration, Chime Biologics and Waterstone will offer a comprehensive solution to the ADC developers for IND-enabling and clinical studies. Leveraging its CMC expertise in biologics, Chime Biologics will manage Antibody Intermediate, ADC Drug Substance and Drug Product process development and cGMP manufacturing. Waterstone will supply Linker-payload, a critical intermediate in the …